scholarly journals Benidipine, a Long-Acting Calcium Channel Blocker, Inhibits Oxidative Stress in Polymorphonuclear Cells in Patients with Essential Hypertension

2005 ◽  
Vol 28 (2) ◽  
pp. 107-112 ◽  
Author(s):  
Kenichi YASUNARI ◽  
Kensaku MAEDA ◽  
Munehiro NAKAMURA ◽  
Takanori WATANABE ◽  
Junichi YOSHIKAWA
Keyword(s):  
Oxidative Stress ◽  
Essential Hypertension ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Polymorphonuclear Cells ◽  
Long Acting

Effects of an Antihypertensive Combination in Japanese Hypertensive Outpatients Based on the Long-Acting Calcium Channel Blocker Benidipine on Vascular and Renal Events: A Sub-Analysis of the COPE Trial

2020 ◽  
Vol 16 ◽  
Author(s):  
Seiji Umemoto ◽  
Toshio Ogihara ◽  
Masunori Matsuzaki ◽  
Hiromi Rakugi ◽  
Kazuyuki Shimada ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Rank Test ◽  
Vascular Events ◽  
Treatment Groups ◽  
Β Blocker ◽  
The Difference ◽  
Long Acting

Background: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events) three benidipine (a calcium channel blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40–85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a β-blocker (n=1,089) or an additional angiotensin receptor blocker (ARB; n=1,110). A significantly higher incidence of hard cardiovascular composite endpoints and of fatal or non-fatal strokes was observed in the benidipine-β-blocker group compared to the benidipine-thiazide group. Objective and Methods: We further evaluated the treatment effects of the three benidipine-based regimens on vascular and renal events in a sub-analysis of the COPE patients. Results: A total of 10 vascular events (0.8 per 1,000 person-years) including one aortic dissection (0.1 per 1,000 person-years) and nine cases of peripheral artery disease (0.8 per 1,000 person-years) were documented, as was a total of seven renal events (0.6 per 1,000 person-years). No significant differences in vascular and renal events were revealed among the three treatment groups: vascular events p=0.92 renal events p=0.16 log-rank test. Conclusions: Blood pressure-lowering therapy with benidipine combined with an ARB, β-blocker, or thiazide was similarly effective in the prevention of vascular and renal events in hypertensive outpatients, although there is no enough these events to compare the difference in the three treatment groups.

On the molecular dynamics in long-acting calcium channel blocker lacidipine: solid-state NMR, neutron scattering and periodic DFT study

RSC Advances ◽  
2016 ◽  
Vol 6 (71) ◽  
pp. 66617-66629 ◽  
Author(s):  
Aleksandra Pajzderska ◽  
Kacper Drużbicki ◽  
Anna Kiwilsza ◽  
Miguel Angel Gonzalez ◽  
Jacek Jenczyk ◽  
...  
Keyword(s):  
Solid State ◽  
Neutron Scattering ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Solid State Nmr ◽  
Channel Blocker ◽  
Inelastic Neutron Scattering ◽  
Inelastic Neutron ◽  
Long Acting ◽  
New Generation

A new-generation lipophilic calcium channel blocker lacidipine (LCDP) has been thoroughly explored by combining solid-state nuclear magnetic resonance (NMR) with high-flux quasi-elastic (QENS) and inelastic neutron scattering (INS) experiments.

Long acting diltiazem tablets

1992 ◽  
Vol 30 (5) ◽  
pp. 20.1-20
Keyword(s):  
Steady State ◽  
Liver Function ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Half Life ◽  
Channel Blocker ◽  
Elimination Half Life ◽  
Elimination Half ◽  
Long Acting

Diltiazem is a calcium channel blocker used mainly to treat angina.1 Two manufacturers have recently introduced longer acting formulations of diltiazem, to be taken twice instead of three times a day. The elimination half-life of the drug ranges between 2 and 11 hours, longer when renal or liver function is impaired. The dosage patients need therefore varies considerably, and must often be titrated. The long acting tablets act for over 12 hours, so that the drug accumulates to reach a steady state in about 3 days.

Sign in / Sign up

Export Citation Format

Share Document